Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics (NASDAQ: TVTX) announced on June 11, 2024, that its Compensation Committee granted inducement equity grants to three new employees on June 10, 2024. These grants, consisting of 10,500 inducement restricted stock units (RSUs), are part of the company's efforts to attract new talent. The RSUs are governed by the terms of Travere's 2018 Equity Incentive Plan but were granted outside of this plan as inducements material to the new hires. The RSUs will vest over four years, with 25% vesting each year, contingent upon the employees' continued service with the company.
Travere Therapeutics announced the issuance of inducement equity grants to five new employees under Nasdaq Listing Rule 5635(c)(4) on May 10, 2024.
The grants include stock options for 25,000 shares and restricted stock units (RSUs) for 26,500 shares of common stock. The stock options have an exercise price of $6.30 per share, the closing price on the date of grant, and vest over a four-year period. The RSUs also vest over four years, with 25% of shares vesting annually.
These inducement grants are intended to attract new talent and are issued outside of Travere's 2018 Equity Incentive Plan but adhere to its terms.
Travere Therapeutics, Inc. (Nasdaq: TVTX) will present data on FILSPARI (sparsentan) at the National Kidney Foundation (NKF) Spring Clinical Meetings and the European Renal Association (ERA) Congress. The presentations showcase FILSPARI's efficacy over traditional treatments, highlighting its benefits in patients with IgA nephropathy.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will be participating in upcoming investor conferences including the BofA Securities Health Care Conference on May 15, 2024, and the Jefferies Global Healthcare Conference on June 5, 2024. The live webcasts of the presentations can be accessed on Travere's website with replays available for 30 days after each event.
Travere Therapeutics reported strong financial results for the first quarter of 2024, showcasing significant growth and achievements in key regulatory milestones. The FDA granted Priority Review for converting FILSPARI to full approval for IgAN in the U.S., with a PDUFA target action date of September 5, 2024. European Commission granted conditional marketing authorization for FILSPARI in Europe. The Company dosed the first patients in the pivotal Phase 3 HARMONY Study and has cash, cash equivalents, and marketable securities totaling $441.0 million as of March 31, 2024.
Travere Therapeutics, Inc. (NASDAQ: TVTX) will report its first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast to discuss the results and provide a business update. Details can be accessed on Travere's Investor page.
Summary not available.
Summary not available.
Summary not available.
Summary not available.